Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Navigate End-To-End Strategic Updates in NASH and Obesity to Define the Evolving Competitive Landscape in Metabolic Disorders
NAFLD is associated with risk factors such as obesity and inflammatory biomarkers and with events including heart attacks and strokes.
For people with NAFLD or NASH, treating metabolic problems may offer benefits beyond liver disease.
Advanced fatty liver disease led to a greater need for medical care and more difficulty with daily activities.
In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.
Men, people with obesity and people who smoke are more likely to develop NAFLD.
Lean people had a higher mortality rate despite experiencing fewer metabolic problems.
Obesity-linked liver disease has increased 131% in the past three decades.
Restoration of gut function and microbial diversity could lead to improvement of hepatic encephalopathy.
The findings could potentially lead to the first FDA approval of a treatment for fatty liver disease.
While hepatitis C remains a leading cause, cirrhosis is increasingly caused by fatty liver disease and alcohol use.
People who used cholesterol-lowering medications had a 40% lower risk for liver disease progression.
The risk for cardiovascular events and all-cause mortality were greatly reduced in people with obesity and fatty liver disease.
An FDA advisory committee expressed concerns about the safety of the fatty liver disease treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.